Advertisement

Medical Oncology

, 32:215 | Cite as

FBXW7 overexpression suppresses renal cancer cell proliferation and induces apoptosis

  • Yu Fu
  • Youcheng Lin
  • Zhao Yang
  • Guosheng Yang
  • Gaoyuan Li
  • Yuejia Liu
  • Xi Tan
  • Yi Huang
  • Xun Wu
  • Yongqiang Wang
  • Hu Xiong
  • Meng Zhang
  • Lu Fang
  • Yukun Ge
  • Jun Zeng
  • Yangke Cai
  • Jian Bai
  • Song Wu
Original Paper

Abstract

FBXW7 gene (F-box and WD-40 domain protein 7) is also named HCDC4 and is a significant tumor suppressor gene, which can regulate human cell cycle, proliferation and differentiation. In this study, we tend to investigate protein expression and related biological functions of FBXW7 gene. FBXW7 expression level in renal cell carcinoma (RCC) tissues is highly related to its clinical pathologic grade (P = 0.0094) and TNM phase (P = 0.0080) and is highly lower than in paracancerous normal tissues through immunohistochemistry study. FBXW7 high-expression patients have overall better prognosis than low-expression patients (P < 0.001). After transfected with FBXW7 plasmid, the RCC cell lines ACHN and A704 showed a depressed proliferation activity and high proportion of apoptosis through CCK8, colony formation and flow cytometry assay studies. By Western blot analysis, expression of cell proliferation-activating protein c-Myc and c-Jun is downregulated in FBXW7 high-expression RCC compared with negative control. These data suggested that FBXW7 is a significant tumor suppressor gene in RCC.

Keywords

FBXW7 RCC Cell cycle Apoptosis Proliferation 

Notes

Conflict of interest

None.

References

  1. 1.
    Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182(1):19–26.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004;303(5662):1374–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Anzi S, Finkin S, Shaulian E. Transcriptional repression of c-Jun’s E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal. 2008;20(5):862–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Isobe T, Hattori T, Kitagawa K, Uchida C, Kotake Y, Kosugi I, Oda T, Kitagawa M. Adenovirus E1A inhibits SCF(Fbw7) ubiquitin ligase. J Biol Chem. 2009;284(41):27766–79.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A, Kitagawa M. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 2009;28(25):2393–405.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, Tsunematsu R, Susaki E, Nakagawa T, Matsumoto A, Nakayama KI. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci. 2006;97(8):729–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI, Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem. 2008;283(45):30540–8.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI, Mori M. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009;69(9):3788–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H, Mori M. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer. 2010;126(8):1828–37.PubMedGoogle Scholar
  10. 10.
    Minella AC, Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005;4(10):1356–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Hagedorn M, Delugin M, Abraldes I, Allain N, Belaud-Rotureau MA, Turmo M, Prigent C, Loiseau H, Bikfalvi A, Javerzat S. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 2007;2:9.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Imura S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, Yamada S, Ishikawa D, Bando Y, Shimada M. The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol. 2014;29(10):1822–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, Assumpcao PP, Khayat AS, Smith MDEA, dos Santos AK, Burbano RR. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 2013;13:141.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Wei G, Wang Y, Zhang P, Lu J, Mao JH. Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. J Cancer Sci Ther. 2012;4(9):299–305.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 1991;56:1–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Blick M, Westin E, Gutterman J, Wong-Staal F, Gallo R, McCredie K, Keating M, Murphy E. Oncogene expression in human leukemia. Blood. 1984;64(6):1234–9.PubMedGoogle Scholar
  18. 18.
    Toft DJ, Rosenberg SB, Bergers G, Volpert O, Linzer DI. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc Natl Acad Sci USA. 2001;98(23):13055–9.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11(8):353–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Xu Y, Tian C, Sun J, Zhang J, Ren K, Fan XY, Wang K, Wang H, Yan YE, Chen C, Shi Q, Dong XP. FBXW7-induced MTOR degradation forces autophagy to counteract persistent prion infection. Mol Neurobiol. 2015. doi: 10.1007/s12035-014-9028-7.Google Scholar
  21. 21.
    Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499–502.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Yu Fu
    • 1
  • Youcheng Lin
    • 3
  • Zhao Yang
    • 4
  • Guosheng Yang
    • 1
  • Gaoyuan Li
    • 1
  • Yuejia Liu
    • 1
  • Xi Tan
    • 2
  • Yi Huang
    • 5
  • Xun Wu
    • 3
  • Yongqiang Wang
    • 5
  • Hu Xiong
    • 8
  • Meng Zhang
    • 5
  • Lu Fang
    • 5
  • Yukun Ge
    • 3
  • Jun Zeng
    • 1
  • Yangke Cai
    • 1
  • Jian Bai
    • 1
  • Song Wu
    • 5
    • 6
    • 7
  1. 1.Department of UrologyUniversity of South China of Collaboration Hospital, Guangdong No. 2 Provincial People’s HospitalGuangzhouChina
  2. 2.Pathology DepartmentUniversity of South China of Collaboration Hospital, Guangdong No. 2 Provincial People’s HospitalGuangzhouChina
  3. 3.Southern Medical UniversityGuangzhouChina
  4. 4.University of Chinese Academy of SciencesBeijingChina
  5. 5.National-Regional Key Technology Engineering Laboratory for Clinical Application of Cancer Genomics, Second People’s HospitalThe First Affiliated Hospital of Shenzhen UniversityShenzhenChina
  6. 6.Zhongshan School of MedicineSun Yat-sen UniversityGuangzhouChina
  7. 7.Luohu Hospital of Shenzhen University, Shenzhen Fifth People’s HospitalShenzhenChina
  8. 8.The Second Hospital of Lanzhou UniversityXianChina

Personalised recommendations